Literature DB >> 27440044

An Organic Anion Transporter 1 (OAT1)-centered Metabolic Network.

Henry C Liu1, Neema Jamshidi1, Yuchen Chen2, Satish A Eraly3, Sai Yee Cho4, Vibha Bhatnagar5, Wei Wu3, Kevin T Bush6, Ruben Abagyan7, Bernhard O Palsson1, Sanjay K Nigam8.   

Abstract

There has been a recent interest in the broader physiological importance of multispecific "drug" transporters of the SLC and ABC transporter families. Here, a novel multi-tiered systems biology approach was used to predict metabolites and signaling molecules potentially affected by the in vivo deletion of organic anion transporter 1 (Oat1, Slc22a6, originally NKT), a major kidney-expressed drug transporter. Validation of some predictions in wet-lab assays, together with re-evaluation of existing transport and knock-out metabolomics data, generated an experimentally validated, confidence ranked set of OAT1-interacting endogenous compounds enabling construction of an "OAT1-centered metabolic interaction network." Pathway and enrichment analysis indicated an important role for OAT1 in metabolism involving: the TCA cycle, tryptophan and other amino acids, fatty acids, prostaglandins, cyclic nucleotides, odorants, polyamines, and vitamins. The partly validated reconstructed network is also consistent with a major role for OAT1 in modulating metabolic and signaling pathways involving uric acid, gut microbiome products, and so-called uremic toxins accumulating in chronic kidney disease. Together, the findings are compatible with the hypothesized role of drug transporters in remote inter-organ and inter-organismal communication: The Remote Sensing and Signaling Hypothesis (Nigam, S. K. (2015) Nat. Rev. Drug Disc. 14, 29). The fact that OAT1 can affect many systemic biological pathways suggests that drug-metabolite interactions need to be considered beyond simple competition for the drug transporter itself and may explain aspects of drug-induced metabolic syndrome. Our approach should provide novel mechanistic insights into the role of OAT1 and other drug transporters implicated in metabolic diseases like gout, diabetes, and chronic kidney disease.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ABC transporter; Recon; SLC transporter; chronic kidney disease; diabetes; genome-scale metabolic reconstruction; kidney; microbiome; pharmacophore; systems biology

Mesh:

Substances:

Year:  2016        PMID: 27440044      PMCID: PMC5016685          DOI: 10.1074/jbc.M116.745216

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

Review 1.  Review on uremic toxins: classification, concentration, and interindividual variability.

Authors:  Raymond Vanholder; Rita De Smet; Griet Glorieux; Angel Argilés; Ulrich Baurmeister; Philippe Brunet; William Clark; Gerald Cohen; Peter Paul De Deyn; Reinhold Deppisch; Beatrice Descamps-Latscha; Thomas Henle; Achim Jörres; Horst Dieter Lemke; Ziad A Massy; Jutta Passlick-Deetjen; Mariano Rodriguez; Bernd Stegmayr; Peter Stenvinkel; Ciro Tetta; Christoph Wanner; Walter Zidek
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

Review 2.  HIV medications: an update and review of metabolic complications.

Authors:  E Kelly Hester
Journal:  Nutr Clin Pract       Date:  2012-02       Impact factor: 3.080

Review 3.  Flexible ligand docking to multiple receptor conformations: a practical alternative.

Authors:  Maxim Totrov; Ruben Abagyan
Journal:  Curr Opin Struct Biol       Date:  2008-02-25       Impact factor: 6.809

4.  Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterization.

Authors:  Peng Duan; Shanshan Li; Ni Ai; Longqin Hu; William J Welsh; Guofeng You
Journal:  Mol Pharm       Date:  2012-09-25       Impact factor: 4.939

Review 5.  The role of transporters in toxicity and disease.

Authors:  John D Schuetz; Peter W Swaan; Donald J Tweedie
Journal:  Drug Metab Dispos       Date:  2014-04       Impact factor: 3.922

Review 6.  Organic anion transporters and their implications in pharmacotherapy.

Authors:  Arian Emami Riedmaier; Anne T Nies; Elke Schaeffeler; Matthias Schwab
Journal:  Pharmacol Rev       Date:  2012-03-28       Impact factor: 25.468

7.  A role for the organic anion transporter OAT3 in renal creatinine secretion in mice.

Authors:  Volker Vallon; Satish A Eraly; Satish Ramachandra Rao; Maria Gerasimova; Michael Rose; Megha Nagle; Naohiko Anzai; Travis Smith; Kumar Sharma; Sanjay K Nigam; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-15

8.  Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1).

Authors:  William R Wikoff; Megha A Nagle; Valentina L Kouznetsova; Igor F Tsigelny; Sanjay K Nigam
Journal:  J Proteome Res       Date:  2011-04-22       Impact factor: 4.466

Review 9.  Is there something special about palmitoleate?

Authors:  Leanne Hodson; Fredrik Karpe
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-03       Impact factor: 4.294

10.  MetaboAnalyst 3.0--making metabolomics more meaningful.

Authors:  Jianguo Xia; Igor V Sinelnikov; Beomsoo Han; David S Wishart
Journal:  Nucleic Acids Res       Date:  2015-04-20       Impact factor: 16.971

View more
  15 in total

Review 1.  The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease.

Authors:  Sanjay K Nigam
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-01-06       Impact factor: 13.820

2.  Gut-derived uremic toxin handling in vivo requires OAT-mediated tubular secretion in chronic kidney disease.

Authors:  Kevin T Bush; Prabhleen Singh; Sanjay K Nigam
Journal:  JCI Insight       Date:  2020-04-09

3.  The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut-liver-kidney axis.

Authors:  Kevin T Bush; Wei Wu; Christina Lun; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2017-08-01       Impact factor: 5.157

4.  Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease.

Authors:  Zeyu Zhang; Maolin Luo; Yongping Lu; Weifeng Feng; Hongwei Wu; Lijing Fan; Baozhang Guan; Yong Dai; Donge Tang; Xiangnan Dong; Chen Yun; Berthold Hocher; Haiping Liu; Qiang Li; Lianghong Yin
Journal:  Int Urol Nephrol       Date:  2022-10-18       Impact factor: 2.266

5.  Blockade of Organic Anion Transport in Humans After Treatment With the Drug Probenecid Leads to Major Metabolic Alterations in Plasma and Urine.

Authors:  Jeffry C Granados; Vibha Bhatnagar; Sanjay K Nigam
Journal:  Clin Pharmacol Ther       Date:  2022-05-22       Impact factor: 6.903

6.  Unique metabolite preferences of the drug transporters OAT1 and OAT3 analyzed by machine learning.

Authors:  Anisha K Nigam; Julia G Li; Kaustubh Lall; Da Shi; Kevin T Bush; Vibha Bhatnagar; Ruben Abagyan; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2020-01-02       Impact factor: 5.157

Review 7.  Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling.

Authors:  Sanjay K Nigam; Kevin T Bush
Journal:  Nat Rev Nephrol       Date:  2019-05       Impact factor: 28.314

8.  Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes.

Authors:  Wei Wu; Kevin T Bush; Sanjay K Nigam
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

Review 9.  The Systems Biology of Drug Metabolizing Enzymes and Transporters: Relevance to Quantitative Systems Pharmacology.

Authors:  Sanjay K Nigam; Kevin T Bush; Vibha Bhatnagar; Samuel M Poloyac; Jeremiah D Momper
Journal:  Clin Pharmacol Ther       Date:  2020-04-11       Impact factor: 6.875

10.  Effect and Mechanism of ShiZhiFang on Uric Acid Metabolism in Hyperuricemic Rats.

Authors:  Yansheng Wu; Yixing Wang; Jiaoying Ou; Qiang Wan; Liqiang Shi; Yingqiao Li; Fei He; Huiling Wang; Liqun He; Jiandong Gao
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-25       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.